LAUSANNE, Switzerland, Feb. 08, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative ...
Oral presentation at AAIC further demonstrates the strength of AC Immune’s Morphomer™ platform for generating highly selective small molecule diagnostics LAUSANNE, Switzerland, July 28, 2020 (GLOBE ...
LAUSANNE, Switzerland - AC Immune SA (NASDAQ:ACIU), a biopharmaceutical company specializing in neurodegenerative diseases, has received Fast Track Designation from the U.S. Food and Drug ...
Under the terms of the agreement AC Immune will provide its world leading expertise in the biology and pathology of Tau as well as committing its laboratory capabilities to support the collaborative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results